INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma.

Completed · Phase 2

Conditions studied: Non-Hodgkin's Lymphoma, Cancer

In brief

Primary objectives * Assess the response rate in patients with recurrent or refractory B-cell NHL or Hodgkins disease, treated with the combination of the gemcitabine and irinotecan. Secondary objectives * Assess progression free survival in these patients treated with this regimen. * Assess toxicity of this regimen in this group of patients.

Key facts

Study ID

NCT00276003

Run by

University of New Mexico

People needed

22

Starts

2002-08-01

Expected to finish

2005-08-01

Last updated by the study team

2010-01-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with a histologic diagnosis of non-HIV related B-cell NHL or Hodgkins disease are eligible.
• Patients should have documented evidence of refractory or relapsed NHL or Hodgkins disease for inclusion.
• Patient should have received 1 or more prior chemotherapeutic regimens for relapse, and should have completed last course of treatment at least 3 weeks prior to enrollment.
• The patient must have bidimensionally measurable or evaluable disease.
• Age > 18 years.
• ECOG Performance status < 2
• Informed consent.
• ANC > 1.5, platelet count > 100K, creatinine< 2.0, bilirubin < 3
• Female patients must have a negative pregnancy test.

Where it is running

• Lovelace Sandia Health Systems Dept of Hematology — Albuquerque, New Mexico, United States
• University of New Mexico — Albuquerque, New Mexico, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.